


Brilliant Violet 510™ anti-mouse CD25

Catalog # / Size:	1110210 / 500 µl 1110205 / 125 µl
Clone:	PC61
Isotype:	Rat IgG1, λ
Immunogen:	IL-2-dependent cytolytic mouse T-cell clone B6.1
Reactivity:	Mouse
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 510™ and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Concentration:	Lot-specific



Con A-stimulated (3 days) Balb/c splenocytes were stained with CD25 (clone PC61) Brilliant Violet 510™ (filled histogram). Unstained control cells are represented by the open histogram.

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:	Additional reported applications (for the relevant formats) include: immunoprecipitation ^{1,2} , <i>in vitro</i> blocking of IL-2 binding to low- and high-affinity receptors ¹⁻⁴ , growth inhibition of IL-2-dependent T-cell lines ¹⁻⁴ , <i>in vivo</i> depletion of CD25 ⁺ CD4 ⁺ Treg cells ^{5-8,10} , and immunohistochemical staining of acetone-fixed frozen sections ² . PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 102014). For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).
---------------------------	--

- Application** 1. Lowenthal JW, *et al.* 1985. *Nature* 315:669. (IP, Block)
- References:** 2. Ceredig R, *et al.* 1985. *Nature* 314:98. (IP, IHC, Block)
3. Lowenthal JW, *et al.* 1985. *J. Immunol.* 135:3988. (Block)
4. Moreau JL, *et al.* 1987. *Eur. J. Immunol.* 17:929. (Block)
5. Takahashi T, *et al.* 2000. *J. Exp. Med.* 192:303. (Deplete)
6. Onizuka S, *et al.* 1999. *Cancer Res.* 59:3128. (Deplete)
7. Lei TC, *et al.* 2005. *Blood* 105:4865. (Deplete)
8. Pasare C, *et al.* 2004. *Immunity* 21:733. (Deplete)
9. León-Ponte M, *et al.* 2007. *Blood* 109:3139.
10. Cao OW, *et al.* 2007. *Blood* doi:10.1182/blood-2007-02-073304. (Deplete)
11. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719.
12. Anguela XM, *et al.* 2013. *Diabetes.* 62:551. [PubMed](#).
-

Description: CD25 is a 55 kD glycoprotein also known as the low affinity IL-2R α , Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2R β) and CD132 (common γ chain), CD25 forms the high affinity signaling IL-2 receptor.

- Antigen** 1. Taniguchi T, *et al.* 1993. *Cell* 73:5.
- References:** 2. Waldmann TA. 1991. *J. Biol. Chem.* 266:2681.
3. Read S, *et al.* 2000. *J. Exp. Med.* 192:295.
4. Lowenthal JW, *et al.* 1985. *J. Immunol.*